Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
申请人:Vertex Pharmaceuticals Incorporated
公开号:US20150231142A1
公开(公告)日:2015-08-20
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
Construction and investigation of photo-switch property of azobenzene-bridged pillar[5]arene-based [3]rotaxanes
作者:Hui Chong、Cuiyun Nie、Lihong Wang、Sicong Wang、Ying Han、Yang Wang、Chengyin Wang、Chaoguo Yan
DOI:10.1016/j.cclet.2020.11.020
日期:2021.1
high-resolution mass, 1H NMR and NOESY spectra. The photo-responsive property were examined by irradiation of the synthesized [3]rotaxanes with 365 nm and blue light LED, which caused trans to cis and cis to trans isomerization, respectively. Irradiation of corresponding model guest compounds without pillar[5]arene encapsulation resulted in near completely trans to cis and cis to trans isomerization, indicating
摘要以亚烷基三唑为轴基,以四氢芴基为封端基,采用螺纹封端法制备了具有不同烷基链长度的客体分子的偶氮苯桥联支柱[5]芳烃基[3]轮烷。通过高分辨率质谱,1 H NMR和NOESY光谱证明了柱[5]芳烃的包封。通过用365 nm和蓝光LED辐射合成的[3]轮烷,分别引起反式至顺式和顺式至反式异构化,检查了光响应特性。辐照没有柱[5]芳烃包封的相应模型客体化合物导致几乎完全反式转化为顺式和顺式为反式异构化,这表明柱[5]芳烃的存在是确定的光异构化效率的决定因素。
1-HALOALKADIENE AND A PROCESS FOR PREPARING THE SAME AND A PROCESS FOR PREPARING (9e, 11z)-9,11-HEXADECADIENYL ACETATE
申请人:SHIN-ETSU CHEMICAL CO., LTD.
公开号:US20190322614A1
公开(公告)日:2019-10-24
A process to prepare (9E,11Z)-9,11-hexadecadienyl acetate with a good yield and high purity of the general formula (1): CH
3
—(CH
2
)
3
—CH═CH—CH═CH—(CH
2
)
a
—X.=The process includes a step of conducting a Wittig reaction between a haloalkenal of the general formula (2): OHC—CH═CH—(CH
2
)
a
—X, and a triarylphosphonium pentylide of the general formula (3): CH
3
—(CH
2
)
3
—CH
−
—P
+
Ar
3
, to obtain the 1-haloalkadiene, and the use of a (7E,9Z)-1-halo-7,9-tetradecadiene obtained by the process for a process of preparing (9E, 11Z)-9,11-hexadecadienyl acetate.
Supported heterogeneous organotin catalysts of the formula X1, X2, or X3:
wherein Z is a spacer group;
Y is an insoluble phenyl-group containing copolymer;
R
1
, R
2
, R
3
, R
5
, and R
6
are independently selected from halogen, alkyl, alkylene, phenyl, vinyl, allyl, naphthyl, aralkyl, and Z; and
R
4
is alkyl, alkylene, phenyl, vinyl, allyl, naphthyl, or aralkyl.
Catalytic Access to Alkyl Bromides, Chlorides and Iodides via Visible Light-Promoted Decarboxylative Halogenation
作者:Lisa Candish、Eric A. Standley、Adrián Gómez-Suárez、Satobhisha Mukherjee、Frank Glorius
DOI:10.1002/chem.201602251
日期:2016.7.11
Herein is reported the catalytic, visiblelight‐promoted, decarboxylative halogenation (bromination, chlorination, and iodination) of aliphatic carboxylicacids. This operationally‐simple reaction tolerates a range of functional groups, proceeds at room temperature, and is redox neutral. By employing an iridium photocatalyst in concert with a halogen atom source, the use of stoichiometric metals such